New estimates indicate that 55 million of the European adult population will have diabetes by the end of 2012, compared to 53 million last year. For us this type of events is essential to empower people with diabetes and to raise the awareness on diabetes. Type 2 diabetes is a condition that represents a serious public health issue and Novartis is committed to improving the lives of people living with it. RESULTS: The prevalence of MS was 50.8%, 41.8% and 41.9% based on the Adult Treatment Panel (ATPIII), the World Health Organisation (WHO), and the International Diabetes Federation (IDF) definitions, respectively. The cost-effectiveness of primary prevention strategies for type 2 diabetes has not been universally demonstrated. However, full implementation has not been achieved. Taking action to address a major cause of premature death, significant morbidity and reduced quality of life represents an important factor in building this public support across the European Union.
People with diabetes in Spain reported spending on average 300 euros per year on their diabetes medicines and devices. This is a considerable amount of money as millions of people in Spain live with a net salary of less than 1000 euros per month. The assessment of entries will be carried out by an independent expert panel. Patients’ perceptions from all other conditions are vital if we are to understand their needs, and then go on to advocate for them. If you do this, however, you may have to manually adjust some preferences every time you visit a site and some services and functionalities may not work. Inadequate access to medicines and devices has dire consequences for people with diabetes and healthcare systems, which are faced with spiraling costs. Adding to this political view is the fact that health care professionals across many disciplines are experiencing the benefit of empowered patients who take a more active role in the management of their disease.
diabetes can manage their condition properly and lead long, healthy and productive lives.” For most countries, the largest single element of diabetes expenditure is hospital admissions for the treatment of diabetes complications. The 2011 congress was held in Dubai with the upcoming 2013 congress will be held in Melbourne. “Good health and high quality healthcare are essential for economic and social development. The economic impact of diabetes is substantial. After all, we are talking about giving people with diabetes the right to be treated well,” concludes João Nabais. Access to diabetes treatment is seriously challenged by several issues in Azerbaijan. First, there is overall lack of transparency and publicly available information about what people with diabetes are actually entitled to and how medicines and devices provided by the healthcare system are selected.
In addition, insufficient or inadequate supply of diabetes medicines and devices is a recurring issue in the country. Also, a majority of people with diabetes simply cannot afford to cover the full costs of their treatment. Even if the government has recently shown more willingness to increase public help, unaffordable diabetes treatment is a major issue in Georgia. Prices for diabetes and devices are not regulated and are reportedly quite high. To date, it has committed more than €88,000,0001 to diabetes research in Europe by various funding means. In general, people with diabetes have to pay for most of their medicines and devices, making it very difficult for them to follow regular and continuous treatment. In Italy, access to diabetes treatment is challenged because of the country’s highly regionalised healthcare system.
This translates into inequalities between regions and sometimes even between cities because prescription criteria for diabetes medicines and devices are different. Most importantly, regionalisation of healthcare in the country strongly impacts the capacity of regions to cover the costs of diabetes treatment. As a direct consequence of the crisis, healthcare budgets in some parts of the country run out prematurely and healthcare authorities can no longer provide free supplies for people with diabetes. In light of all these issues, diabetes associations advocating for the rights of people with diabetes play more than ever a crucial role. “Because of the crisis, our government wants to rationalise costs on health, and therefore on diabetes. Recently a draft bill was proposed to provide all people with diabetes in Italy with the same medicines and devices. Thanks to intense lobbying, diabetes associations limited the damage and obtained that people with diabetes get the most suitable treatment on doctor’s prescription,” commented Michele Sette, 21, living with type 1 diabetes.
Access to diabetes treatment in Portugal has been affected by austerity measures. Local healthcare centres have had to reduced their staff or have simply closed down. This makes it harder for people living outside big cities to access the treatment and information they need. How to tackle unfair trading practises (UTPs) is a burning question, especially for food producers who stumble over the… Portugal currently has national quotas on insulin pumps, leading to waiting lists of sometimes up to 2 years for people who are eligible to get the device. In addition, people with diabetes -either type 1 or type 2- in Romania are treated by diabetologists, i.e. specialised healthcare professionals.
Usually these healthcare professionals are based in larger a city. This makes consultation harder for people living further away from urban areas. Shortages and unaffordable treatment are the two main barriers for people with diabetes to access their treatment in Serbia. Very limited public health spending on diabetes means that prescription and reimbursement for diabetes medicines and devices are tightly controlled and highly conditioned. Regionalisation is the main challenge to equal access to diabetes treatment in Sweden. Regional or local authorities are responsible for the implementation of prescription criteria and for financing certain medical devices. This inevitably leads to inequalities in access to diabetes treatment.
In this respect, a recent decision by Swedish authorities to transfer responsibility for financing insulin pumps and continuous glucose monitoring devices (CGM – devices to monitor blood-glucose levels at any time) to regions is making people with diabetes and diabetes association anxious. Right now these two devices are still free of charge if prescribed by a doctor but the diabetes community fears that once regions will have to decide on their financial coverage, fewer people will be able to receive insulin pumps and CGMs. Even if prescription guidelines are defined at national level, implementation and resources do not always follow locally. This leads to inequalities as to the type and quantity of medicines and devices a person with diabetes can get, depending on where they live. In a recent study carried out by Diabetes UK, 39% of both people with type 1 and type 2 diabetes using self-monitoring devices reported being refused a prescription for blood glucose test strips or having their prescription restricted. In such cases, people with diabetes have either to accept what they have been prescribed or buy the missing supplies out of their own pockets. The IDF Europe study on Access to Quality Medicines and Medical Devices for Diabetes Care in Europe highlights disparities in access to quality medicines and medical devices for diabetes care in the 47 countries of the IDF Europe Region.
Articulated around three key dimensions of access to healthcare (availability, accessibility and affordability), the study aims to provide evidence to policy makers and stakeholders on the current challenges faced by people living with diabetes in terms of access to the treatment they need. The study is based on a total of 1150 answers to a survey questionnaire sent out to the 47 countries of the IDF Europe Region, interviews and desk research. Respondents are people with diabetes, healthcare professionals, diabetes advocates, academics and public and private stakeholders. IDF Europe is the European Region of the International Diabetes Federation. We are an umbrella organisation uniting 66 diabetes associations in 47 countries. We represent people with diabetes and their families, as well as health professionals working in diabetes. Through our work, we aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of best practice and high-quality information about diabetes in all countries throughout the Region.